OvaScience to Host Fourth Quarter and Fiscal Year 2015 Financial Results Conference Call

Sigue a La Raza en Facebook

WALTHAM, Mass.–(BUSINESS WIRE)–OvaScienceSM (NASDAQ: OVAS), a global fertility company
focused on the discovery, development and commercialization of new
treatment options, announced today that it will host a conference call
at 4:30 p.m. EST on Thursday, February 25, 2016 to discuss fourth
quarter and fiscal year 2015 financial results and provide a general
corporate update.

The live call can be accessed by dialing +1 888 424 8151 for U.S.
callers and +1 847 585 4422 for international callers five minutes prior
to the start of the call and providing the passcode 5767395. A live
webcast of the conference call will be available online from the
Investors section of the Company’s website at www.ovascience.com.

A replay of the conference call will be available from 7:00 p.m. EST on
Thursday, February 25, 2016, through 11:59 p.m. EST on Thursday, March
3, 2016, and may be accessed by visiting OvaScience’s website or by
dialing +1 888 843 7419 for U.S. callers and +1 630 652 3042 for
international callers. The replay access code is 5767395.

About OvaScience
OvaScience (NASDAQ: OVAS) is a global
fertility company dedicated to improving treatment options for women
around the world. OvaScience is discovering, developing and
commercializing new fertility treatments because we believe women
deserve more options. Each OvaScience treatment is based on the
Company’s proprietary technology platform that leverages the
breakthrough discovery of egg precursor (EggPCSM) cells –
immature egg cells found inside the protective ovarian lining. The
AUGMENTSM treatment, a fertility option specifically designed
to improve egg health, is available in certain IVF clinics in select
international regions. OvaScience has commenced a non-commercial
preceptorship training program with the OvaPrimeSM treatment,
which could increase a woman’s egg reserve, and is developing the OvaTureSM treatment,
a potential next-generation IVF treatment that could help a woman
produce healthy, young, fertilizable eggs without hormone injections.
OvaScience treatments are not available in the U.S. For more
information, please visit www.ovascience.com
and www.augmenttreatment.com
and connect with us on Twitter
and Facebook.

Forward-Looking Statements
This press release includes
forward-looking statements about the Company’s plans for the AUGMENT
treatment, OvaPrime treatment and OvaTure treatment. Actual results may
differ materially from those indicated by these forward-looking
statements as a result of various important factors, including risks
related to:
the possibility that international IVF clinics that
we work with may determine not to provide or
continue providing
the AUGMENT treatment, or to delay such treatment based on clinical
efficacy, safety or commercial, logistic, regulatory or other reasons;
the science underlying our treatments (including the AUGMENT, OvaPrime
and OvaTure treatments), which is unproven; our ability to obtain
regulatory approval or licenses where necessary for our treatments; our
ability to develop our treatments on the timelines we expect, if at all;
our ability to commercialize our treatments, on the timelines we expect,
if at all; as well as those risks more fully discussed in the “Risk
Factors” section of our most recently filed Quarterly Report on Form
10-Q and/or Annual Report on Form 10-K. The forward-looking statements
contained in this press release reflect our current views with respect
to future events. We anticipate that subsequent events and developments
will cause our views to change. However, while we may elect to update
these forward-looking statements in the future, we specifically disclaim
any obligation to do so. These forward-looking statements should not be
relied upon as representing our view as of any date subsequent to the
date hereof.

###

Contacts

OvaScience
Rebecca J. Peterson, 617-420-8736
rpeterson@ovascience.com